The Department of Hematology, in cooperation with the other departments of the German Medical Institute (GMI), offers the most modern approach to diagnosing and treating hematological diseases.
The most novel developments in molecular medicine are implemented in all treatment plans for all hematological diseases. These include:
• Benign hematological diseases, such as anemia, thrombocytopenia, and hemostatic disorders
• Hematological malignancies, such as leukemia, lymphoma, multiple myeloma, and myeloproliferative neoplasms.
Our upcoming Bone Marrow Transplant and New Cell Therapies Unit will be the first of its kind in Cyprus. It will cover cellular therapies for hematological and non-hematological diseases such as:
• Autologous and allogeneic hematopoietic cell transplants for hematological malignancies
• Autologous hematopoietic cell transplants for non-hematological malignancies and autoimmune diseases (e.g., for solid tumors, multiple sclerosis)
New cell therapies for the treatment of hematological malignancies (CAR-T cells) and inherited diseases (e.g., gene therapy for beta-thalassemia)
The Department of Hematology
The Department of Hematology
The Department of Hematology
We need your consent before you can continue on our website.
If you are under 16 and wish to give consent to optional services, you must ask your legal guardians for permission.
We use cookies and other technologies on our website. Some of them are essential, while others help us to improve this website and your experience.
Personal data may be processed (e.g. IP addresses), for example for personalized ads and content or ad and content measurement.
You can find more information about the use of your data in our privacy policy.
There is no obligation to consent to the processing of your data in order to use this offer.
You can revoke or adjust your selection at any time under Settings.
Please note that based on individual settings not all functions of the site may be available.
Some services process personal data in the USA. With your consent to use these services, you also consent to the processing of your data in the USA pursuant to Art. 49 (1) lit. a GDPR. The ECJ classifies the USA as a country with insufficient data protection according to EU standards. For example, there is a risk that U.S. authorities will process personal data in surveillance programs without any existing possibility of legal action for Europeans.